Health
Novo Sees Ozempic Shortages Continuing Next Year in Europe
This article is for subscribers only.
Novo Nordisk A/S expects shortages of Ozempic and Victoza to continue next year in Europe as demand soars for diabetes drugs that can also help with weight loss.
For both medicines, shortages will get worse as the end of this year approaches, according to a letter to health care professionals published on Tuesday by the European Medicines Agency. For Ozempic, intermittent shortages will then probably continue through 2024, while for Victoza, shortages will last until at least the second quarter.